{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T04:37:36Z","timestamp":1772771856650,"version":"3.50.1"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2023,12,23]],"date-time":"2023-12-23T00:00:00Z","timestamp":1703289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"},{"start":{"date-parts":[[2023,12,23]],"date-time":"2023-12-23T00:00:00Z","timestamp":1703289600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,23]],"date-time":"2023-12-23T00:00:00Z","timestamp":1703289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sotagliflozin is a dual sodium-glucose co-transporter 1 and 2 inhibitor that increases glucosuria and natriuresis in patients with\u00a0type 2 diabetes mellitus (T2DM). However, the safety and efficacy in patients with\u00a0concomitant chronic kidney disease (CKD) remains unclear. Therefore, we aimed to conduct a meta-analysis to evaluate the current evidence\u00a0in this regard.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched PubMed, Embase, Cochrane, and Web of Science for randomized controlled clinical trials on the safety and efficacy of Sotagliflozin in patients with T2DM and CKD compared with placebo. Statistical analysis was performed using RevMan 5.4. Heterogeneity was assessed with I2 statistics. The study was recorded in\u00a0PROSPERO registry (CRD42023449631).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results\u00a0<\/jats:title>\n                    <jats:p>We included three studies totaling 11,648 patients followed for 15.7\u2009\u00b1\u20095.9\u00a0months. Reduction in HbA1C (mean difference \u2212\u20090.33%; 95% CI [\u2212\u20090.54, \u2212\u20090.11]; p\u2009=\u20090.003; I2\u2009=\u2009100%) and weight (mean difference \u2212\u20091.01\u00a0kg; 95% CI [\u2212\u20091.17, \u2212\u20090.86]; p\u2009&amp;lt;\u20090.00001; I2\u2009=\u200996%) were significantly higher in the Sotagliflozin group compared with placebo. All-cause mortality (RR 0.98; 95% CI [0.81, 1.20]; p\u2009=\u20090.87; I2\u2009=\u20090%) and major adverse cardiovascular events (RR 0.70; 95% CI [0.40, 1.21]; p\u2009=\u20090.20; I2\u2009=\u200939%) were not significantly different between groups. However, estimated glomerular filtration rate reduction (mean difference \u2212\u20090.95; 95% CI [\u2212\u20091.32, \u2212\u20090.58]; p\u2009&amp;lt;\u20090.00001; I2\u2009=\u200998%), genital mycotic infections (RR 2.73; 95% CI [1.96, 3.79]; p\u2009&amp;lt;\u20090.00001; I2\u2009=\u20090%), diarrhea (RR 1.42; 95% CI [1.24. 1.63]; p\u2009&amp;lt;\u20090.00001; I2\u2009=\u20090%) and volume depletion (RR 1.31; 95% CI [1.11, 1.56]; p\u2009=\u20090.002; I2\u2009=\u20090%) were more common with Sotagliflozin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients with T2DM and CKD, Sotagliflozin appears to be effective for glycemic control and weight loss. Although the medication seemed safe concerning mortality and cardiovascular events, it induced estimated glomerular filtration rate reduction, and was associated with a higher risk of\u00a0genital mycotic infections, diarrhea, and volume depletion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s40620-023-01818-2","type":"journal-article","created":{"date-parts":[[2023,12,23]],"date-time":"2023-12-23T05:02:16Z","timestamp":1703307736000},"page":"881-896","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Safety and efficacy of sotagliflozin in patients with type II diabetes mellitus and chronic kidney disease: a meta-analysis of randomized controlled trials"],"prefix":"10.1093","volume":"37","author":[{"given":"Rafael","family":"dos Santos Borges","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil 1"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustavo","family":"de Oliveira Almeida","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Universidade Federal do Tri\u00e2ngulo Mineiro, Uberaba, MG, Brazil 2"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vin\u00edcius Freire Costa","family":"Alves","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Universidade de S\u00e3o Paulo, S\u00e3o Paulo, SP, Brazil 3"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thiago Faraco","family":"Nienkotter","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Universidade do Sul de Santa Catarina, Palho\u00e7a, SC, Brazil 4"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edmundo Damiani","family":"Bertoli","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Universidade do Sul de Santa Catarina, Palho\u00e7a, SC, Brazil 4"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9222-3882","authenticated-orcid":false,"given":"Ana Cristina","family":"Sim\u00f5es e Silva","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil 1"},{"name":"Interdisciplinary Laboratory of Medical Investigation, Unit of Pediatric Nephrology, Faculty of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil 5"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,12,23]]},"reference":[{"issue":"10365","key":"2026010918132584400_CR1","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/S0140-6736(22)01655-5","article-title":"Type 2 diabetes","volume":"400","author":"Ahmad","year":"2022","journal-title":"Lancet Lond Engl"},{"key":"2026010918132584400_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2019.107843 31518657","article-title":"Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the international diabetes federation diabetes atlas, 9th edition","volume":"157","author":"Saeedi","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"issue":"11","key":"2026010918132584400_CR3","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1001\/jama.297.11.1197 17374814","article-title":"One-year cardiovascular event rates in outpatients with atherothrombosis","volume":"297","author":"Steg","year":"2007","journal-title":"JAMA"},{"issue":"12","key":"2026010918132584400_CR4","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1001\/jama.2010.1322 20805624","article-title":"Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis","volume":"304","author":"Bhatt","year":"2010","journal-title":"JAMA"},{"issue":"2","key":"2026010918132584400_CR5","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1001\/jama.295.2.180 16403930","article-title":"International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis","volume":"295","author":"Bhatt","year":"2006","journal-title":"JAMA"},{"issue":"10","key":"2026010918132584400_CR6","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1161\/CIRCULATIONAHA.114.014796 26152709","article-title":"Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the reduction of atherothrombosis for continued health (REACH) registry","volume":"132","author":"Cavender","year":"2015","journal-title":"Circulation"},{"issue":"14","key":"2026010918132584400_CR7","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684 23992601","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"issue":"5","key":"2026010918132584400_CR8","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/S2213-8587(15)00044-3 25791290","article-title":"Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials","volume":"3","author":"Udell","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"2026010918132584400_CR9","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1001\/jamacardio.2016.3030 27681000","article-title":"Prognostic implications of biomarker assessments in patients with type 2 diabetes at high cardiovascular risk: a secondary analysis of a randomized clinical trial","volume":"1","author":"Scirica","year":"2016","journal-title":"JAMA Cardiol"},{"issue":"6","key":"2026010918132584400_CR10","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/j.kint.2016.09.010 27884312","article-title":"Management of patients with diabetes and CKD: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) controversies conference","volume":"90","author":"Perkovic","year":"2016","journal-title":"Kidney Int"},{"key":"2026010918132584400_CR11"},{"issue":"12","key":"2026010918132584400_CR12","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.2337\/dci22-0027 36189689","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: improving global outcomes (KDIGO)","volume":"45","author":"de Boer","year":"2022","journal-title":"Diabetes Care"},{"issue":"24","key":"2026010918132584400_CR13","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1056\/NEJMoa1708337 28899222","article-title":"Effects of sotagliflozin added to insulin in patients with type 1 diabetes","volume":"377","author":"Garg","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"2026010918132584400_CR14","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1111\/dom.14127 32618383","article-title":"Sotagliflozin added to optimized insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: a pooled analysis of inTandem1 and inTandem2","volume":"22","author":"Rodbard","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"2026010918132584400_CR15","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.2337\/dc14-2806 26049551","article-title":"Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes","volume":"38","author":"Sands","year":"2015","journal-title":"Diabetes Care"},{"issue":"4","key":"2026010918132584400_CR16","doi-asserted-by":"publisher","first-page":"e1235","DOI":"10.1210\/clinem\/dgz258 31837264","article-title":"Sotagliflozin decreases postprandial glucose and insulin concentrations by delaying intestinal glucose absorption","volume":"105","author":"Powell","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2026010918132584400_CR17","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.2337\/dc18-0343 29937430","article-title":"Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: the North American inTandem1 Study","volume":"41","author":"Buse","year":"2018","journal-title":"Diabetes Care"},{"issue":"9","key":"2026010918132584400_CR18","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.2337\/dc18-0342 29937431","article-title":"HbA1c and hypoglycemia reductions at 24 and 52 weeks with sotagliflozin in combination with insulin in adults with type 1 diabetes: the European inTandem2 Study","volume":"41","author":"Danne","year":"2018","journal-title":"Diabetes Care"},{"issue":"10","key":"2026010918132584400_CR19","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1007\/s00125-018-4669-0 30132034","article-title":"The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure","volume":"61","author":"Thomas","year":"2018","journal-title":"Diabetologia"},{"issue":"6","key":"2026010918132584400_CR20","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004 32613148","article-title":"Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC Basic Transl Sci"},{"issue":"8","key":"2026010918132584400_CR21","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1111\/dme.13645","article-title":"Sotagliflozin: a dual sodium-glucose co-transporter-1 and -2 inhibitor for the management of type 1 and type 2 diabetes mellitus","volume":"35","author":"Sims","year":"2018","journal-title":"Diabet Med J Br Diabet Assoc"},{"issue":"6","key":"2026010918132584400_CR22","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1111\/dom.15019 36782093","article-title":"Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease","volume":"25","author":"Cherney","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"2026010918132584400_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71 33782057","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026010918132584400_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898 31462531","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2026010918132584400_CR25"},{"key":"2026010918132584400_CR26"},{"issue":"6","key":"2026010918132584400_CR27","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1177\/0962280216669183 27683581","article-title":"Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range","volume":"27","author":"Luo","year":"2018","journal-title":"Stat Methods Med Res"},{"issue":"14","key":"2026010918132584400_CR28","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"19","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"2026010918132584400_CR29"},{"issue":"1","key":"2026010918132584400_CR30","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2337\/db11-1029 22124465","article-title":"Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion","volume":"61","author":"Gorboulev","year":"2012","journal-title":"Diabetes"},{"issue":"2","key":"2026010918132584400_CR31","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1152\/physrev.00055.2009 21527736","article-title":"Biology of human sodium glucose transporters","volume":"91","author":"Wright","year":"2011","journal-title":"Physiol Rev"},{"issue":"9","key":"2026010918132584400_CR32","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1007\/s00424-014-1619-7 25304002","article-title":"Localizations of Na(+)-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart","volume":"467","author":"Vrhovac","year":"2015","journal-title":"Pflugers Arch"},{"issue":"2","key":"2026010918132584400_CR33","doi-asserted-by":"publisher","first-page":"F188","DOI":"10.1152\/ajprenal.00518.2013","article-title":"Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia","volume":"306","author":"Rieg","year":"2014","journal-title":"Am J Physiol Ren Physiol"},{"issue":"2","key":"2026010918132584400_CR34","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s13300-010-0006-4","article-title":"Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members","volume":"1","author":"Chen","year":"2010","journal-title":"Diabetes Ther Res Treat Educ Diabetes Relat Disord"},{"key":"2026010918132584400_CR35","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3389\/fphar.2014.00274 25540623","article-title":"Use of systems pharmacology modeling to elucidate the operating characteristics of SGLT1 and SGLT2 in renal glucose reabsorption in humans","volume":"5","author":"Lu","year":"2014","journal-title":"Front Pharmacol"},{"issue":"2","key":"2026010918132584400_CR36","doi-asserted-by":"publisher","first-page":"G241","DOI":"10.1152\/ajpgi.00310.2001 11804845","article-title":"Expression of monosaccharide transporters in intestine of diabetic humans","volume":"282","author":"Dyer","year":"2002","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"12","key":"2026010918132584400_CR37","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.2337\/diabetes.54.12.3427 16306358","article-title":"Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes","volume":"54","author":"Rahmoune","year":"2005","journal-title":"Diabetes"},{"issue":"2","key":"2026010918132584400_CR38","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1172\/JCI117010 8113395","article-title":"Small intestine hexose transport in experimental diabetes. Increased transporter mRNA and protein expression in enterocytes","volume":"93","author":"Burant","year":"1994","journal-title":"J Clin Investig"},{"issue":"2","key":"2026010918132584400_CR39","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/clpt.2012.58 22739142","article-title":"LX4211, a dual SGLT1\/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial","volume":"92","author":"Zambrowicz","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"2026010918132584400_CR40","doi-asserted-by":"publisher","first-page":"73","DOI":"10.4137\/CMED.S31526 26523120","article-title":"Canagliflozin treatment in patients with type 2 diabetes mellitus","volume":"8","author":"Triplitt","year":"2015","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"issue":"2","key":"2026010918132584400_CR41","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1177\/1479164114563304 25690134","article-title":"Development of sotagliflozin, a dual sodium-dependent glucose transporter 1\/2 inhibitor","volume":"12","author":"Lapuerta","year":"2015","journal-title":"Diab Vasc Dis Res"},{"issue":"2","key":"2026010918132584400_CR42","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa2030186 33200891","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"2026010918132584400_CR43","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1111\/dom.14513 34338408","article-title":"Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment","volume":"23","author":"Cherney","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"2026010918132584400_CR44","doi-asserted-by":"publisher","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004 16908915","article-title":"Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate","volume":"145","author":"Levey","year":"2006","journal-title":"Ann Intern Med"},{"issue":"5S","key":"2026010918132584400_CR45","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group","year":"2022","journal-title":"Kidney Int"},{"issue":"4","key":"2026010918132584400_CR46","doi-asserted-by":"publisher","first-page":"845","DOI":"10.2337\/dc22-2003 36787983","article-title":"Glomerular hyperfiltration predicts kidney function decline and mortality in type 1 and type 2 diabetes: a 21-year longitudinal study","volume":"46","author":"Moriconi","year":"2023","journal-title":"Diabetes Care"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-023-01818-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-023-01818-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/37\/4\/881\/66020619\/joneph_37_4_1818.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-023-01818-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/37\/4\/881\/66020619\/joneph_37_4_1818.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T23:13:31Z","timestamp":1768000411000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/37\/4\/881\/8306812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,23]]},"references-count":46,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,12,23]]},"published-print":{"date-parts":[[2024,5,1]]}},"URL":"https:\/\/doi.org\/10.1007\/s40620-023-01818-2","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5,1]]},"published":{"date-parts":[[2023,12,23]]},"assertion":[{"value":"7 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors certify that they have no affiliations with, or involvement in, any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"For this type of study, formal consent is not required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}